Injectable bisphosphonates for the treatment of osteoporosis.

[en] Bisphosphonates are the current mainstay of the management of osteoporosis worldwide. Oral daily and weekly formulations have been linked to poor adherence, yielding a decrease in antifracture efficacy, in real-life settings. Development of new bisphosphonates, with increased antiosteoclastic potency and affinity for bone matrix allowed intravenous administration and intervals between dosings to be higher than weekly. Ibandronate and zoledronic acid have been investigated in established osteoporosis. Quarterly injections of ibandronate (3 mg) have been shown to be at least as effective in increasing bone mineral density and reducing bone turnover markers as the oral ibandronate regimen, which has proven antifracture efficacy. A once-yearly infusion of zoledronic acid (5 mg) during a 3-year period significantly reduced the risk of vertebral, hip and other fractures. Intravenous administration of bisphosphonates can now be considered as an important component of the management of postmenopausal osteoporosis.

Disciplines :

General & internal medicine

Author, co-author :

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé

Burlet, Nansa

Close, P.

Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé

Language :

English

Title :

Injectable bisphosphonates for the treatment of osteoporosis.

Publication date :

2007

Journal title :

Women's Health

ISSN :

1745-5057

eISSN :

1745-5065

Publisher :

Future Medicine, United Kingdom

Volume :

Issue :

Pages :

719-23

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 04 February 2011

Statistics

Number of views

48 (17 by ULiège)

Number of downloads

9 (9 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Boonen S, Body JJ, Boutsen Y, Devogelaer JP: Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteopros Int. 16, 239-254 (2005).
Reginster JY, Rabenda V, Neuprez A: Adherence, patient preference and dosing frequency: understanding the relationship. Bone 38, S2-S6 (2006).
de Groen PC, Lubbe DF, Hrsch LJ et al.: Esophagitis associated with the use of alendronate. N. Engl. J. Med. 335, 1016-1021 (1996).
Reginster JY, Rabenda V: Adherence to anti-osteoporotic treatment: does it really matter? Future Rheumatol. 1(1), 37-40 (2006).
Reginster JY: Adherence and persistence: impact on outcomes and health care resources. Bone 38, S18-S21 (2006).
Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin. Ther. 23, 1296-1310 (2001).
Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM: Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin. Ther. 28, 236-242 (2006).
Thiebaud D, Burckhardt P, Melchior J et al.: Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporos. Int. 4, 76-83 (1994).
Peretz A, Body JJ, Dumon JC et al.: Cyclical pamidronate infusions in postmenopausal osteoporosis. Maturitas 25, 69-75 (1996).
Armingeat T, Brondino, R, Pham T, Legré V, Lafforque P: Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study. Osteoporos. Int. 17, 1659-1665 (2006).
Chesnut CH 3rd, Skag A, Christiansen C et al.: Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res. 19, 1241-1249 (2004).
Delmas PD, Adami S, Strugala C et al.: Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 54, 1838-1846 (2006).
Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL: Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann. Rheum. Dis. 65, 654-661 (2006).
Reginster JY: Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review. Curr. Pharm. Des. 11, 3711-3728 (2005).
Reid IR, Miller P, Lyles K et al.: Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N. Engl. J. Med. 353, 898-908 (2005).
Reid IR, Brown JP, Burckhardt P et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. 346, 653-661 (2002).
Black DM, Dehnas PD, Eastell R et al.: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 18, 1809-1822 (2007).
Devogelaer JP, Brown JP, Burckhardt P et al.: Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteporas Int 18(9), 1211-1218 (2007).
Polascik TJ, Given RW, Metzger C et al.: Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology 66, 1054-1059 (2005).